Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Published:2006-05-03 Issue:3 Volume:8 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Powles Trevor,Paterson Alexander,McCloskey Eugene,Schein Phil,Scheffler Bobbi,Tidy Alwynne,Ashley Sue,Smith Ian,Ottestad Lars,Kanis John

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1186/bcr1413/fulltext.html

Reference1 articles.

1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research. 2006, 8: R13-10.1186/bcr1384.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone-Targeted Agents and Metastasis Prevention;Cancers;2022-07-26

2. Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience;Journal of Bone Oncology;2021-12

3. Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis;Gut and Liver;2021-09-15

4. The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2019-01

5. Unproven Efficacy of Low-Dose Bisphosphonates as a Means of Decreasing Bone Metastases and Death in Early Breast Cancer;JAMA Oncology;2018-11-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3